[1] |
Pinto B, Deo P, Sharma S, et al. Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment[J]. Clin Rheumatol, 2021, 40(10): 3883-3896.
doi: 10.1007/s10067-021-05711-w
pmid: 33791889
|
[2] |
Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2[J]. N Engl J Med, 2014, 370(10): 911-920.
doi: 10.1056/NEJMoa1307361
|
[3] |
Zhang B, Sun Y, Xu N, et al. Adult-onset deficiency of adenosine deaminase 2—a case report and literature review[J]. Clinical Rheumatology, 2021, 40(10): 4325-4339.
doi: 10.1007/s10067-021-05587-w
|
[4] |
张冰清, 张硕, 王涛, 等. 第544例结节红斑—血小板减少—青斑样血管病—免疫缺陷[J]. 中华医学杂志, 2021, 101(31): 2485-2487.
|
[5] |
柏翠, 郭兴青, 高婷婷, 等. 儿童腺苷脱氨酶2缺乏症2例并文献复习[J]. 中华实用儿科临床杂志, 2020, 35(21): 1674-1677.
|
[6] |
Human A, Pagnoux C. Diagnosis and management of ADA2 deficient polyarteritis nodosa[J]. Int J Rheum Dis, 2019, 22 (Suppl 1): 69-77.
doi: 10.1111/apl.2019.22.issue-S1
|
[7] |
Fayand A, Chasset F, Boutboul D, et al. DADA2 diagnosed in adulthood versus childhood: A comparative study on 306 patients including a systematic literature review and 12 French cases[J]. Semin Arthritis Rheum, 2021, 51(6): 1170-1179.
doi: 10.1016/j.semarthrit.2021.09.001
|
[8] |
Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment[J]. J Clin Immunol, 2018, 38(5): 569-578.
doi: 10.1007/s10875-018-0525-8
pmid: 29951947
|
[9] |
Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study[J]. Ann Rheum Dis, 2017, 76(10): 1648-1656.
doi: 10.1136/annrheumdis-2016-210802
pmid: 28522451
|
[10] |
Caratsch L, Schnider C, Moi L, et al. Adenosine deaminase 2 deficiency: a disease with multiple presentations[J]. Rev Med Suisse, 2022, 18(776): 669-673.
doi: 10.53738/REVMED.2022.18.776.669
pmid: 35385618
|
[11] |
Sharma A, Naidu G, Sharma V, et al. Deficiency of adenosine deaminase 2 in adults and children: experience from India[J]. Arthritis Rheumatol, 2021, 73(2): 276-285.
doi: 10.1002/art.v73.2
|
[12] |
Nanthapisal S, Murphy C, Omoyinmi E, et al. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases[J]. Arthritis Rheumatol, 2016, 68(9): 2314-2322.
doi: 10.1002/art.v68.9
|
[13] |
Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, et al. ADA2 deficiency mimicking idiopathic multicentric castleman disease[J]. Pediatrics, 2018, 142(3): e20172266.
doi: 10.1542/peds.2017-2266
|
[14] |
Van Montfrans JM, Hartman EA, Braun KP, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations[J]. Rheumatology (Oxford), 2016, 55(5): 902-910.
doi: 10.1093/rheumatology/kev439
pmid: 26867732
|
[15] |
Westendorp WF, Nederkoorn PJ, Aksentijevich I, et al. Unexplained early-onset lacunar stroke and inflammatory skin lesions: Consider ADA2 deficiency[J]. Neurology, 2015, 84(20): 2092-2093.
doi: 10.1212/WNL.0000000000001581
pmid: 25888558
|
[16] |
Batu ED, Karadag O, Taskiran EZ, et al. A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations[J]. J Rheumatol, 2015, 42(8): 1532-1534.
doi: 10.3899/jrheum.150024
pmid: 26233953
|
[17] |
Uettwiller F, Sarrabay G, Rodero MP, et al. ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters[J]. RMD Open, 2016, 2(1): e000236.
doi: 10.1136/rmdopen-2015-000236
|
[18] |
Schena F, Penco F, Volpi S, et al. Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients[J]. Eur J Immunol, 2021, 51(1): 206-219.
doi: 10.1002/eji.v51.1
|
[19] |
Lee PY, Kellner ES, Huang Y, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)[J]. J Allergy Clin Immunol, 2020, 145(6): 1664-1672.
doi: S0091-6749(20)30030-0
pmid: 31945408
|
[20] |
Özen S, Batu ED, Taşkıran EZ, et al. A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2[J]. J Rheumatol, 2020, 47(1): 117-125.
doi: 10.3899/jrheum.181384
pmid: 31043544
|
[21] |
Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy[J]. N Engl J Med, 2014, 370(10): 921-931.
doi: 10.1056/NEJMoa1307362
|
[22] |
Van Eyck L Jr., Hershfield MS, Pombal D, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency[J]. J Allergy Clin Immunol, 2015, 135(1): 283-287.
doi: 10.1016/j.jaci.2014.10.010
pmid: 25457153
|
[23] |
Garg N, Kasapcopur O, Foster J, 2nd, et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy[J]. Eur J Pediatr, 2014, 173(6): 827-830.
doi: 10.1007/s00431-014-2320-8
pmid: 24737293
|
[24] |
郭莉, 卢美萍. 腺苷脱氨酶2缺乏症研究进展[J]. 中华儿科杂志, 2020, 58(6): 520-523.
|
[25] |
Zhang B, Xu N, Chen J, et al. Treatment and outcome in deficiency of adenosine deaminase 2: a literature review[J]. J Investig Allergol Clin Immunol, 2021, 32(1): 13-22.
doi: 10.18176/jiaci
|
[26] |
Ombrello AK, Qin J, Hoffmann PM, et al. Treatment strategies for deficiency of adenosine deaminase 2[J]. The New England journal of medicine, 2019, 380(16): 1582-1584.
doi: 10.1056/NEJMc1801927
pmid: 30995379
|
[27] |
Gibson KM, Morishita KA, Dancey P, et al. Identification of novel adenosine deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis[J]. Arthritis Rheumatol, 2019, 71(10): 1747-1755.
doi: 10.1002/art.v71.10
|
[28] |
Lee PY. Vasculopathy, Immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2[J]. Front Pediatr, 2018, 6: 282.
doi: 10.3389/fped.2018.00282
|